How to Qualify for Weight Loss Injections on the NHS

You've been told about these injections and you're wondering where you stand

Most people reaching this page have already heard about tirzepatide (Mounjaro) or semaglutide (Wegovy) — from a friend, a news story, or a GP mentioning they might become available on the NHS soon. The common assumption is that a high BMI alone gets you through the door. That's understandable, but it isn't quite how the NHS criteria work, and knowing the actual picture saves a lot of frustration.

The NHS rollout of weight-loss injections is phased, meaning different groups of patients become eligible at different points in time. According to NICE's technology appraisal of tirzepatide (TA1026), published in December 2024 and updated in September 2025, NHS access to tirzepatide is structured around a combination of BMI and the presence of specific weight-related health conditions, not BMI alone. The full detail of those phases is set out on our NHS weight-loss injections overview.

There's also a practical detail that surprises people: even once a phase opens, your local integrated care board sets the pace. Participation is not uniform across England. Some GP practices began prescribing under the 2026/27 GP contract from April 2026; others have not yet joined the scheme. Scotland, Wales and Northern Ireland operate under different thresholds and different commissioning arrangements entirely.

The specific numbers: BMI, conditions and the current phase

As of summer 2026, the NHS phases for tirzepatide run as follows. The first cohort, active from June 2025, requires a BMI of 40 or above plus four or more of the five named conditions. Those five are: high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. The second cohort, which the NHS England guidance confirmed opened on 23 June 2026, extends to adults with a BMI of 35–39.9 who also meet the same four-or-more-conditions bar. A further phase from around March 2027 is expected to cover BMI 40 or above with three qualifying conditions.

For adults from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the BMI thresholds are each 2.5 kg/m² lower, so 37.5 instead of 40, for example, in the current phase. The NHS tirzepatide page explains these medicines and who they are licensed for at a patient level.

Semaglutide (Wegovy) sits under a separate NICE recommendation (TA875) and is currently accessible on the NHS only through specialist weight management services, with its own eligibility criteria and typically longer waiting lists than primary care routes. You can read more about how to pursue that route in our step-by-step guide to getting a weight-loss injection on the NHS.

One thing worth knowing about the cost side: if you're considering what private treatment runs while you wait, a realistic breakdown of what weight-loss injections cost privately may help you plan.

If you meet the criteria, what actually happens next?

Qualifying on paper is the beginning, not the end. Every NHS patient prescribed a weight-loss injection is required to take part in a wraparound support programme, dietary guidance, physical activity support and regular monitoring. This isn't optional; it's a condition of the prescription. Your GP or specialist will also need to review whether you have any contraindications, discuss other medicines you take, and confirm your weight by a verifiable method.

If you believe you meet the current criteria, the practical next steps are either a GP appointment or a referral to a specialist weight management service, depending on which medicine is being sought and which pathway is available in your area. Our guide on applying for NHS weight-loss injections walks through the referral process in plain terms. The full eligibility detail, including ethnic-background adjustments and the coming phases, is covered there too.

If you don't meet the NHS criteria right now

This is where the picture diverges for a lot of people. Many adults with a BMI of 30 or above, or 27 and above with a weight-related condition such as prediabetes or high cholesterol, are licensed candidates for these medicines privately, even though the NHS thresholds sit much higher. The licensed eligibility criteria set by the MHRA for private prescribing are broader than the NHS commissioning criteria, because the NHS applies a health-economics filter on top of the clinical licence.

A regulated private pharmacy with a GPhC-registered prescriber can assess your suitability independently of the NHS queue, and our guide on how to get weight loss injections explains what that process involves from start to finish. At nume, every consultation is read by a real prescriber (not automated software) on the day it's submitted. Our clinical team is described on the clinical team page if you'd like to understand who's reviewing your information. The weight-loss treatment overview covers both medicines currently available through our pharmacy.

If the NHS route feels like the right one for you but you're unsure whether you currently qualify, speaking to a prescriber privately is also a way to get a clear clinical assessment of where you stand. When you're ready to take that step, speak to our prescribers through a free consultation.